Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs ResMed Inc. — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.65, while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| JEPQ | RMD | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $293.73 |
52-Week Low | $53.77 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $58.59, up 0.14% with a bearish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with covered-call strategies, generating monthly income through dividends. Recent distributions include $0.64, $0.56, and $0.59 per share, highlighting its income-oriented approach. Technical indicators show neutral oscillators but overall bearish momentum with key support at $57.
The outlook remains cautious due to technical bearishness and capped upside from covered calls. Investment appeal centers on high distribution yields for income-focused investors, though performance may lag pure Nasdaq-100 ETFs during rallies. Risks include strategy underperformance in bull markets and dependency on options income sustainability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
